Steve joined Engine Biosciences as Chief Scientific Officer in May 2018. Prior to joining Engine, Steve was Senior Vice President and CSO at Relypsa where he developed a pipeline of gut-restricted polymer therapeutics targeting systemic diseases. Before that he was Vice President, Research Biology at Nektar Therapeutics (NASDAQ: NKTR), a leader in polymer conjugate therapeutics, where for four years he managed global oncology and pain research efforts. Prior to Nektar, he was Senior Vice President, Research at KAI Pharmaceuticals. While at KAI, Steve led discovery efforts, including the company’s lead compound for the treatment of secondary hyperparathyroidism, which served as the basis for the company’s eventual acquisition by Amgen. Earlier in his career, Steve held senior research positions at Chiron Corporation and Thios Pharmaceuticals. He holds a Ph.D. in Molecular Biology, a M.A. and B.A. in Biochemistry, all from University of Cambridge, England.
Target and Biomarker Identification Using ML and CRISPR Screening
Engine Biosciences is uniquely applying proprietary machine-learning algorithms and ultra high-throughput CRISPR-based validation technology to identify clinically relevant targets and patient selection biomarkers in oncology. In our talk we would outline the differentiating features of the technology platform and showcase case studies of successful target and biomarker discovery leading to drug development programs.